Synonyms: example 86 [WO2014093383]
Compound class:
Synthetic organic
Comment: ARN-3236 is an orally active, ATP-competitive inhibitor of salt-inducible kinases (SIKs) [3]. It is one of the chemical structures claimed in patent WO2014093383, in which it is referred to as Example 86 or compound 114 [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Lombardi MS, Gilliéron C, Dietrich D, Gabay C. (2016)
SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype. J Leukoc Biol, 99 (5): 711-21. [PMID:26590148] |
2. Vankayalapati H, Yerramreddy V, Ganipisetty VB, Talluri S, Appalaneni RP. (2014)
Substituted 1h-pyrrolo [2,3-b] pyridine and 1h-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors. Patent number: WO2014093383. Assignee: Arrien Pharmaceuticals Llc. Priority date: 14/12/2012. Publication date: 19/06/2014. |
3. Zhou J, Alfraidi A, Zhang S, Santiago-O'Farrill JM, Yerramreddy Reddy VK, Alsaadi A, Ahmed AA, Yang H, Liu J, Mao W et al.. (2017)
A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. Clin Cancer Res, 23 (8): 1945-1954. [PMID:27678456] |